semaglutide and bone loss (Ozempic) linked to fewer fractures despite greater weight POTD: Wegovy and Ozempic —

Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline

Exenatide was extracted from the injection pen and was diluted with a vehicle solution (pH = 4.5, acetate buffer with mannitol) containing the main components of the original vehicle from the product to achieve a larger dosing volume (0.1 mL/kg) set based on individual body weight

injection of poly-I:C induces IL-1 expression in microglia/macrophages at least partly via direct action of poly-I:C

This tracks with Amgens MariTide and looks to be outpacing Lillys ZEPBOUND